Silence Therapeutics is a biotechnology company focused on discovering and developing molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with unmet medical need. Co.'s wholly owned pipeline is focused in three therapeutic areas of unmet need: cardiovascular disease, hematology and rare diseases. Co.'s wholly owned product candidates are: SLN360, which is an siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood; and SLN124, which is an siRNA molecule designed to treat erythropoiesis. We show 2 historical shares outstanding datapoints in our SLN shares outstanding history coverage, used to compute SLN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing SLN market cap history over the course of time is important for investors
interested in comparing SLN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of SLN versus a peer is one thing; comparing
SLN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like SLN can fluctuate over the course of history.
With this page we aim to empower investors researching SLN by allowing them to research the SLN market cap history. |
Free SLN Email Alerts:
Video: The Importance of Market Cap
